Table 2.
EQ-5D-3L VAS scores by group
| Dimension of the score | P-VKA (n=89) | S-DOAC (n=50) | P-DOAC (n=52) | Statistical test, p-value |
|---|---|---|---|---|
| Mobility | ||||
| No problems | 46% | 56% | 67% | Chi-2=6.1, p=0.47a |
| Moderate/extreme problems | 54% | 44% | 33% | |
| Self-care | ||||
| No problems | 82% | 90% | 88% | Chi-2=2.1, p=0.35a |
| Moderate/extreme problems | 18% | 10% | 12% | |
| Usual activities | ||||
| No problems | 69% | 74% | 75% | Chi-2=0.85, p=0.66a |
| Moderate/extreme problems | 31% | 26% | 25% | |
| Pain/discomfort | ||||
| No problems | 53% | 40% | 65% | Chi-2=6.7, p=0.036a |
| Moderate/extreme problems | 47% | 60% | 35% | |
| Anxiety/depression | ||||
| No problems | 42% | 44% | 56% | Chi-2=2.8, p=0.25a |
| Moderate/extreme problems | 58% | 56% | 44% | |
| VAS: mean score (SD) | 65 (16) | 69 (17) | 65 (16) | F2,188=1.3, p=0.29b |
Notes:
a
Proportional odds likelihood ratio test;
b
Kruskal–Wallis test.
Abbreviations: DOAC, direct oral anticoagulant; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels; P-DOAC, primary DOAC; P-VKA, primary VKA; S-DOAC, switch from VKA to DOAC; VAS, visual analog scale; VKA, vitamin K antagonists.